3 results about "Clinical treatment" patented technology

The invention discloses a veterinary compound tilmicosin injection and a preparation method thereof. 100ml of the veterinary compound tilmicosin injection comprises 15-30g of tilmicosin, 4-10g of florfenicol, 0.5-1.0g of an anti-oxidant, 3.3-8.0g of a cosolvent and the balance injection water. The veterinary compound tilmicosin injection having stable performances is prepared from tilmicosin and florfenicol as main raw materials and the anti-oxidant and the cosolvent as auxiliary materials. After intramuscular injection, the veterinary compound tilmicosin injection can be easily absorbed by animals and even completely absorbed, improves bioavailability, has long drug active ingredient action time, can be used for clinical treatment on livestock and poultry respiratory tract system disease caused by a plurality of pathogenic bacteria, has good curative effects and is convenient for use. The preparation method of the veterinary compound tilmicosin injection has simple processes, is convenient for operation and is suitable for large-scale industrial production.

The invention relates to a drug for treating broken bones by fast reunion of muscles and bones, which is characterized by being a traditional Chinese medicine preparation prepared by the following raw materials based on the parts by weight: 50-70 of eucommia bark, 40-50 of achyranthes, 20-35 of sweet vernal grass, 10-20 of rice, 10-20 of pepper, 55-70 of erberry, 20-35 of sandalwood, 20-35 of Oxalis rubra St. Hil., 15-30 of bracteolate fissistigma root-bark and 10-20 of wood sorrel. When the drug is used for curing broken bone and damaged muscles, the skeletal muscle at the broken bone generally rapidly heals up by 3 days, and the person can move after 7 days; and the drug can cure a child only by one course of treatment (7 days) clinically, can achieve the effects of bone generation and muscle union, has functions in treating broken bones, muscle injury and soft tissue injury, promoting blood circulation by removing blood stasis and reunion of muscles and bones, not only saves time and money, but also has safe treatment and no toxic and side effects, and can cure sequela left former injury, hyperosteogeny, and the like except for bone reunion. The drug has high cure rate, no recurrence, simple manufacture, no toxic and side effects, convenient use and low cost and is suitable for both young and old.

The invention belongs to the field of biological medicine, and relates to application of TROAP in preparation of renal cell carcinoma prognosis products and therapeutic drugs. Experiments find and prove that the TROAP gene can promote proliferation, migration and invasion of renal carcinoma cells and inhibit apoptosis at the same time, and is a very important marker for renal carcinoma progression. On the basis, the TROAP gene is used as a screened molecular marker, the prognosis condition of a renal cell carcinoma patient is judged by detecting the expression level of the TROAP, clinical treatment is guided through a prognosis model, and the application has important practical application value for evaluating the prognosis of the patient and guiding the individualized treatment of the patient. Meanwhile, the ROAP gene serves as a targeted drug development action target, a new inhibitor and a new drug development target are provided for the renal clear cell carcinoma, especially metastatic clear cell carcinoma, and the early warning capacity and the subsequent treatment effect on the patients of the type are improved.